Lenvatinib and Pembrolizumab Combo Breaks New Ground in Non–Clear Cell RCC

Laurence Albiges discussed effective treatments for various non–clear cell renal cell carcinoma (nccRCC) subtypes at the 2024 Kidney Cancer Research Summit. Treatments include combinations like cabozantinib/nivolumab for papillary RCC, lenvatinib/pembrolizumab for chromophobe RCC, and immuno-oncology plus tyrosine kinase inhibitor for translocation RCC. Challenges include small patient numbers and the need for more data on adjuvant strategies.